Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17375
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Nagoya University
• Principal Investigator: Hanajiri Ryo 名古屋大学, 医学部附属病院, 助教 (40861810)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 免疫療法 / 細胞療法 / 抗原特異的T細胞 / HLA / 臍帯血 / キメラ抗原受容体

Outline of Final Research Achievements

This study focused on the target antigen, cell source, and metabolic state of T-cells to enhance the therapeutic efficacy of antigen-specific T-cell therapy targeting multiple antigens and chimeric antigen receptor gene transfer T-cell therapy for refractory hematologic malignancies including adult T-cell leukemia and lymphoma. It was suggested that overlapping peptides as antigens and umbilical cord blood as a cell source could be used for developing the adoptive immune T-cell product, and furthermore, manipulation of the intracellular metabolic state of T-cells could lead to improvement of T-cell function.

Free Research Field

血液内科学

Academic Significance and Societal Importance of the Research Achievements

養子免疫T細胞療法において、１）抗原エピトープが不明な場合でもオーバーラッピングペプチドによる抗原特異的T細胞の作製が可能であること、２）細胞源として成人と比較しより多くのナイーブT細胞が含まれる臍帯血が利用可能であること、３）T細胞の代謝制御による機能向上により、より高い抗腫瘍効果を発揮するT細胞製剤の開発につながる可能性がある。